Omeros Corporation (OMER)

Dec 21, 2024

Wellington Management Group LLP Invests $305,000 in Omeros Co. (NASDAQ:OMER) - MarketBeat

Dec 21, 2024

Dec 21, 2024

Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER) - Defense World

Dec 21, 2024

Dec 21, 2024

Omeros Corporation Announces Positive Results for Narsoplimab in Treating Thrombotic MicroangiopathyOn December 19, 2024, Omeros Corporation (NASDAQ: OMER) revealed the outcomes of a primary statistical analysis involving narsoplimab, the comp - Defense World

Dec 21, 2024

Dec 20, 2024

Omeros' (OMER) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat

Dec 20, 2024

Dec 20, 2024

BNP Paribas Financial Markets Buys 7,016 Shares of Omeros Co. (NASDAQ:OMER) - Defense World

Dec 20, 2024

Dec 20, 2024

Omeros (NASDAQ:OMER) Reaches New 12-Month HighStill a Buy? - MarketBeat

Dec 20, 2024

Dec 19, 2024

Stock Of The Day / 12.19.24 / OMER for NASDAQ:OMER by AlexX31 - TradingView

Dec 19, 2024

Dec 19, 2024

Top Midday Gainers - Marketscreener.com

Dec 19, 2024

Dec 19, 2024

Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN

Dec 19, 2024

Dec 19, 2024

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges - Benzinga

Dec 19, 2024

Dec 19, 2024

Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat

Dec 19, 2024

Dec 19, 2024

Omeros Stock Gains 52% On Successful Trial Results - MarketWatch

Dec 19, 2024

Dec 19, 2024

Omeros antibody improves overall survival by 68% in rare condition, new analysis finds - Fierce Biotech

Dec 19, 2024

Dec 19, 2024

Omeros stock soars to 52-week high, hits $12.65 - Investing.com

Dec 19, 2024

Dec 19, 2024

Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges - Yahoo Finance

Dec 19, 2024

Dec 19, 2024

Omeros stock surges on positive survival data for narsoplimab - Investing.com

Dec 19, 2024

Dec 19, 2024

Omeros stock jumps after trial outcome (OMER:NASDAQ) - Seeking Alpha

Dec 19, 2024

Dec 19, 2024

Omeros reports survival benefit with narsoplimab in TA-TMA - Investing.com

Dec 19, 2024

Dec 19, 2024

Omeros announces narsoplimab trial meets primary endpoint - TipRanks

Dec 19, 2024

Dec 19, 2024

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA - Business Wire

Dec 19, 2024

Dec 18, 2024

Omeros (STU:3O8) Operating Income : €-159.24 Mil (TTM As of Sep. 2024) - GuruFocus.com

Dec 18, 2024

Dec 18, 2024

Omeros (STU:3O8) GF Score : 50/100 (As of Dec. 18, 2024) - GuruFocus.com

Dec 18, 2024

Dec 14, 2024

Omeros Co. (NASDAQ:OMER) Short Interest Down 16.9% in November - MarketBeat

Dec 14, 2024

Dec 12, 2024

Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates - Seeking Alpha

Dec 12, 2024

Dec 11, 2024

Omeros Corporation (OMER) Stock Drops Amid Financial Report Conc - GuruFocus.com

Dec 11, 2024

Dec 10, 2024

Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges - MSN

Dec 10, 2024

Dec 10, 2024

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting - BioSpace

Dec 10, 2024

Dec 10, 2024

Omeros reports progress on PNH treatment zaltenibart - Investing.com

Dec 10, 2024

Dec 10, 2024

Omeros reports progress on PNH treatment zaltenibart By Investing.com - Investing.com UK

Dec 10, 2024

Dec 07, 2024

Omeros (NASDAQ:OMER) Stock Price Up 7.8%What's Next? - MarketBeat

Dec 07, 2024

Dec 06, 2024

Omeros stock soars to 52-week high, hits $12.55 By Investing.com - Investing.com Australia

Dec 06, 2024

Dec 06, 2024

Omeros stock soars to 52-week high, hits $12.55 - Investing.com

Dec 06, 2024

Dec 04, 2024

Omeros Corporation (OMER) Stock Surges Amidst Biotech Sector Gai - GuruFocus.com

Dec 04, 2024

Dec 02, 2024

Omeros Corp (OMER) Stock Surges Amid Biotech Sector Activity - GuruFocus.com

Dec 02, 2024

Dec 02, 2024

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting - The Bakersfield Californian

Dec 02, 2024

Nov 30, 2024

(OMER) Trading Advice - Stock Traders Daily

Nov 30, 2024

Nov 26, 2024

Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com

Nov 26, 2024

Nov 23, 2024

Omeros (NASDAQ:OMER) Hits New 12-Month HighHere's Why - MarketBeat

Nov 23, 2024

Nov 22, 2024

Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News - Yahoo Finance

Nov 22, 2024

Nov 22, 2024

Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN

Nov 22, 2024

Nov 22, 2024

Omeros stock soars to 52-week high, hits $7.53 By Investing.com - Investing.com Australia

Nov 22, 2024

Nov 22, 2024

Omeros nears resubmission of narsoplimab BLA By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 21, 2024

Omeros nears resubmission of narsoplimab BLA - Investing.com India

Nov 21, 2024

Nov 21, 2024

Omeros stock soars to 52-week high, hits $7.53 - Investing.com

Nov 21, 2024

Nov 21, 2024

Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Business Wire

Nov 21, 2024

Nov 20, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN

Nov 20, 2024

Nov 20, 2024

StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat

Nov 20, 2024

Nov 20, 2024

Omeros (NASDAQ:OMER) Upgraded at StockNews.com - Defense World

Nov 20, 2024

Nov 19, 2024

Long Term Trading Analysis for (OMER) - Stock Traders Daily

Nov 19, 2024

Nov 18, 2024

IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR

Nov 18, 2024